Corporate Presentation – FY2024 Interim Results

Content Page

3

Results

Highlights

4

2024 Interim Results Highlights

• The Group has changed its name from "Huayi Tencent Entertainment Company Limited" to "Hony Media Group" during the period. On one hand, it continued to optimize its existing internet healthcare business, while on the other hand, it completed the issuance of convertible bonds to an entity under Hony Capital. Mr. Zhao John Huan, Chairman of Hony Capital, was appointed as the Chairman of the Board of Directors of the Company, and Mr. Cheng Wu was appointed as the Chief Executive Officer, focusing on the strategic development of international culture, media and entertainment businesses
• Benefiting from continuous cost control and the business restructuring of the smart healthcare services platform "Meerkat Health", the loss from continuing operations during the period significantly narrowed by 31% to approximately HK$46.18 million from approximately HK$67.21 million during the same period last year
• "Echartnow", the digitized operation service in the healthcare industry, was the main source of revenue for the Group, recording revenue of HK$373 million (same period in 2023: HK$482 million) during the period, representing a decrease of 23% compared to the same period last year, mainly due to changes in business structure and customer structure under the healthcare reform policy. The number of contracted pharmaceutical companies continued to grow, increasing by 24.5% compared to the end of 2023. The platform covers registered doctors in key departments such as pediatrics, oncology, and cardiovascular, with the number of registered doctors increasing by 32.6% compared to the end of 2023
• During the Period, "Meerkat Health" has further terminated the private e-commerce business with unclear development prospects and fully reduced related personnel, focusing on operating the healthcare consumption business and recorded HK$116 million (same period in 2023: HK$148 million), representing a decrease of 21% compared to the same period last year. It is due to the revenue from the same period last year included approximately HK$11.57 million from divested businesses such as vaccines and health examinations; and the proportion of lower-margin business was reduced, concentrating resources on expanding high-margin,high-potential businesses. The segment loss during the period significantly narrowed by 86% to HK$4.58 million (same period in 2023: HK$32.76 million)

5

"Echartnow", provision of digitized operation service in the healthcare industry

6

''Echartnow'' Platform Key Data(30/6/2024)

305

(+24.5%)

Contracted

Pharmaceutical

Companies

HK$373M

• As of 30 June 2024, the number of pharmaceutical companies that have signed up with the Echartnow platform has increased to 305, increasing by 24.5% compared to the end of 2023, including well-known companies such as Qilu Pharmaceutical and CSPC Pharmaceutical Group
• Echartnow platform has now covered 53,150 doctors, increasing by 32.6% compared to the end of 2023 . All doctors have completed real-name registration, uploaded qualification documents, and passed authentication.

9

''Echartnow'' Outlook

• Echartnow will continue to closely follow national policy directions, actively respond to the comprehensive and normalized requirements of anti-corruption in healthcare, deepen the construction of compliance systems, and assist in the legal and compliant digital transformation of the industry. Through open cooperation, Echartnow will share the results of digital transformation with the industry, promoting the deepening of industry digital transformation. At the same time, it will seize policy signals supporting innovation, assist in the research and development and marketing processes of biopharmaceuticals, meet clinical needs, and promote high-quality development of the healthcare industry.
• Echartnow will actively participate in and promote the formulation and implementation of compliance standards for digital operations in the biopharmaceutical industry. Leveraging the platform resource advantages of the Consortium, it will formulate digital operation compliance standards that meet the actual needs of the industry. Through the implementation of the "Biopharmaceutical Digital Operation Compliance Guidelines", it will standardize service processes, improve service efficiency, ensure data security, and promote the industry's advancement towards standardization and intellectualization. At the same time, Echartnow will strengthen ESG (Environmental, Social, and Governance) innovation practices to achieve green and sustainable development, improve public health standards, and promote social employment and economic development.
• Echartnow will also actively engage in in-depth exploration with government departments in areas such as public data authorization, assetization, and circulation transactions. By integrating medical insurance and industry data, it will provide precise market insights and R&D support for biopharmaceutical enterprises, accelerating enterprise growth. At the same time, it will promote the deep integration of pharmaceutical digital marketing and R&D innovation, using big data and AI technologies to optimize marketing strategies and feed back into new drug R&D, jointly promoting the digital transformation and high-quality development of the industry. It will also advance the first domestic customer data asset entry into financial statements and data asset financing, realizing the circulation and transaction of data elements, and enhancing the leading role of the biopharmaceutical industry in data asset applications.

10